Invenra’s Expansion of Collaboration with Exelixis

Fenwick & West represented Invenra Inc. in its expanded collaboration with Exelixis, Inc.

Exelixis (Nasdaq: EXEL) and Invenra had entered into a collaboration on May 2, 2018, to discover and develop multispecific antibodies through the use of Invenra’s B-BodyTMtechnology platform.

The new collaboration will continue to use the Invenra antibody discovery capabilities to generate additional biologics-based programs.

Invenra Inc., is a biotechnology company focused on the discovery and development of multispecific antibodies for immuno-oncology and autoimmunity.

Exelixis, Inc. operates as a development-stage biotechnology company focuses on discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases.

The Fenwick transaction team included technology transactions partner Stefano Quintini (Picture) and licensing attorney Amy Manning.

Involved fees earner: Amy Manning – Fenwick & West LLP; Stefano Quintini – Fenwick & West LLP;

Law Firms: Fenwick & West LLP;

Clients: Invenra Inc.;

Author: Ambrogio Visconti